Next Article in Journal
The Pathogenic Mechanism of Enterocytozoon hepatopenaei in Litopenaeus vannamei
Next Article in Special Issue
FibroScan® versus Biochemical Scores: A Study of Liver Fibrosis in HIV with HBV Co-Infection
Previous Article in Journal
Current and Ongoing Developments in Targeting Clostridioides difficile Infection and Recurrence
Previous Article in Special Issue
Epidemiology of Viral Hepatitis in the Indigenous Populations of the Arctic Zone of the Republic of Sakha (Yakutia)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 12
Issue 6
10.3390/microorganisms12061207
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hepatitis B Virus Prevalence among HIV-Uninfected People Living in Rural and Peri-Urban Areas in Botswana

by
Motswedi Anderson
1,2,3,
Thabo Mangogola
1,4,
Bonolo B. Phinius
1,5,
Gorata Mpebe
1,6,
Christopher O. Aimakhu
4,
Wonderful T. Choga
1,5,
Basetsana Phakedi
1,
Lynnette N. Bhebhe
1,
Doreen Ditshwanelo
1,
Kabo Baruti
1,6,
Linda Mpofu-Dobo
1,7,
Lebogang Othusitse
1,
Tsholofelo Ratsoma
1,6,
Tendani Gaolathe
1,8,
Joseph Makhema
1,9,
Roger Shapiro
1,9,
Shahin Lockman
1,9,10,
Sikhulile Moyo
1,9,11,12 and
Simani Gaseitsiwe
1,9,*
1
Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana
2
Africa Health Research Institute, Durban 4013, South Africa
3
The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
4
Pan-African University (Life and Earth Sciences Institute), University of Ibadan, Ibadan 200132, Nigeria
5
School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana
6
Department of Biological Sciences, Faculty of Science, University of Botswana, Private Bag UB 0022, Gaborone, Botswana
7
Department of Biological Sciences and Biotechnology, Faculty of Sciences, Botswana International University of Science and Technology, Private Bag 16, Palapye, Botswana
8
Faculty of Medicine, University of Botswana, Private Bag UB 0022, Gaborone, Botswana
9
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
10
Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA 02115, USA
11
Division of Medical Virology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Stellenbosch, Private Bag X1, Matieland 7602, South Africa
12
School of Health Systems and Public Health, University of Pretoria, Private Bag X20, Pretoria 0028, South Africa
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Microorganisms 2024, 12(6), 1207; https://doi.org/10.3390/microorganisms12061207
Submission received: 7 May 2024 / Revised: 10 June 2024 / Accepted: 12 June 2024 / Published: 15 June 2024
(This article belongs to the Special Issue Control and Elimination of Viral Hepatitis)
Browse Figures
Versions Notes

Abstract

:
(1) Background: we determined the prevalence of the hepatitis B virus (HBV) amongst people without human immunodeficiency virus (HIV) in rural and peri-urban areas in Botswana. (2) Methods: We screened for the hepatitis B surface antigen (HBsAg) from archived plasma samples of people without HIV (n = 2135) randomly selected from the Botswana Combination Prevention Program (BCPP) (2013–2018). We sequenced 415 bp of the surface region using BigDye sequencing chemistry. (3) Results: The median age of participants was 31 (IQR: 24–46) and 64% (1360/2135) were female. HBV prevalence was 4.0% (86/2135) [95% CI: 3.3–4.9]) and ranged between 0–9.2%. Older participants (>35 years) had increased odds of HBV positivity (OR: 1.94; 95% CI: [1.32–2.86]; p = 0.001). Thirteen samples were sequenced and seven (53.8%) were genotype A, three (23.1%) were genotype D and genotype E each. Clinically significant mutations were identified in the surface region, but no classic drug resistance mutations were identified. (4) Conclusions: We report an HBV prevalence of 4.0% (95% CI 3.3–4.9) among people without HIV in rural and peri-urban communities in Botswana with varying rates in different communities. A comprehensive national HBV program is required in Botswana to guide HBV prevention, testing and management.

1. Introduction

Approximately 254 million people worldwide are infected with chronic hepatitis B virus infections (CHB), with most cases prevalent in the Western Pacific region and sub-Saharan Africa, where 96.8 million and 64.7 million people are affected, respectively [1]. In Botswana, hepatitis B surface antigen (HBsAg) prevalence ranging between 1.1% and 10.6% has been reported in blood donors, pregnant women and mostly in people with human immunodeficiency virus (PWH) [2,3,4,5,6,7,8]. Most of these studies were in urban areas except for the largest HBV study in PWH in the country which was conducted in rural and peri-urban areas [4]. This study reported an overall prevalence of 8% with varying prevalence rates between communities some differing by as much as 10-fold (2.1–22.1%) [4]. Several studies reported similar HBV prevalence rates in PWH and those without, while others reported differences [7,9,10].
HBV is classified into 10 genotypes (A-I) and a putative genotype J based on a nucleotide divergency of >7.5% with more than 35 subgenotypes [11,12,13]. Genotypes differ by geographic distribution and by disease progression [13,14,15]. In Africa, including in Botswana, genotypes A, D and E have been reported [8,14,16]. Subgenotype A1 predominantly found in Africa has been linked with increased chronicity and faster progression to hepatocellular carcinoma [14,15].
One of the barriers to elimination, especially in Africa, is the lack of national data hence most of the national HBV prevalence rates have been extrapolated from the little data available within the region [10,17,18]. In Botswana, there is no prevalence data of HBV at the population level among people without HIV; therefore, we aimed to establish the HBV prevalence amongst people without HIV across rural and peri-urban areas in Botswana.

2. Materials and Methods

2.1. Study Population

Archived plasma samples from people without HIV who were enrolled in the Botswana Combination Prevention Project (BCPP) were used. BCPP was a pair-matched, cluster-randomized trial conducted in 30 communities (15 pairs matched according to size, pre-existing health services, population age structure and geographical location, including proximity to urban areas) around Botswana from 30 October 2013 to 24 November 2018 [19]. BCPP enrolled 12,610 participants aged 16–64 years, of whom 9014 were without HIV [20]. A total of 2135 samples from people without HIV were randomly selected for characterization in this study ensuring proportional distributions amongst the communities. Out of 30 BCPP communities, 2 were not sampled (Otse and Molapowabojang) because there were no stored samples available for these sites. The participants distribution per community is shown in Table 1 below. Samples were stored at −80 °C prior to testing.

2.2. Ethical Approval

Approval for the study was sought from the Institute of Advanced Medical Research and Training (IAMRAT) approval number UI/EC/22/0001 and the Human Research Development Committee (HRDC) at the Botswana Ministry of Health (MoH), HRDC number 01028. Participants provided written informed consent for their samples to be used in the parent study as well as subsequent studies.

2.3. Serological Assays

2.3.1. Validation of the HBsAg Dilution Protocol

Plasma samples had insufficient volumes, so they were diluted using the previously validated in-house protocol shown below. Briefly, archived plasma samples from people with HIV (PWH) from the Botswana Combination Prevention Project (BCPP) were used for the validation of the HBsAg dilution protocol. Samples from PWH were used because they had enough sample volume to allow for the validation. Twenty-four HBsAg positive samples with known optical densities (ODs) were used. The samples were divided into three categories: high positive (OD > 4.9, n = 6), medium positives (OD range 2.0–4.9, n = 9) and low positives (OD range 0–1.9, n = 9) based on their ODs. Serial dilutions of 1:10, 1:100, 1:1000 and 1:100,000 of sample: phosphate buffered saline (PBS) were performed. HBsAg was then screened in the samples with the various dilutions using the Murex HBsAg Version 3 enzyme-linked immunosorbent assay (ELISA) kit (Murex Biotech, Dartford, UK) following manufacturer’s instructions. The results showed that all high and medium positives remain positive from the 1:10 to the 1:10,000 dilutions. The low positives were all positive at the 1:10 dilution; however, (4/9) 44% of low positives lost HBsAg at the 1:100 dilution and an additional (3/9) 33% lost the HBsAg positivity by the 1:1000 dilution. These results show that regardless of the OD, 10−1 dilution remains positive.

2.3.2. HBsAg Screening

Plasma samples had insufficient volumes, so they were diluted using the previously validated in-house protocol shown above. Briefly, prior to HBsAg screening, samples were diluted using PBS at a 10-fold dilution which detects 100% of samples with positive HBsAg serology (HBsAg+) including those with low optical densities. After dilution, the samples were screened for HBsAg using a Murex HBsAg Version 3 enzyme-linked immunosorbent assay (ELISA) kit (Murex Biotech, Dartford, UK). HBsAg+ samples were subsequently repeated for confirmation following the manufacturer’s guidelines.

2.4. Amplification and Sequencing

Total nucleic acid was extracted from 200 μL of HBsAg+ plasma samples diluted with PBS at 10-fold using an in-house validated protocol. We used the QIAamp DNA Blood (QIAGEN, Hilden, Germany) following the manufacturer’s instructions with an elution volume of 30 μL [21]. A 415 bp fragment of the surface/polymerase gene was amplified by semi-nested PCR with two rounds of amplification using Platinum Taq DNA Polymerase High Fidelity kit according to the manufacturer (Invitrogen, Waltham, MA, USA), using primers and thermal cycling conditions as described previously [16,22]. Sequencing was performed using big dye sequencing chemistry. Briefly, the master mix for sequencing PCR consisted of 3 µL Sequencing Buffer (5×), 1 µL BigDye®Terminator v3.1, 0.2 µL of 2 µM Primer, 1 µL purified PCR product and 4.8 µL in a 10 µL reaction mix. The cycling conditions were 5 min denaturing at 94 °C, and then 30 cycles of denaturing for 45 s at 94 °C, annealing for 30 s at 50 °C, and elongation at 72 °C for 90 s, with extension at 72 °C for 10 min using HBV840 (5′-GTTTAAATGTATACCCAAAGAC-3′; nt840–861) and HBV381 (5′-TGCGGCGTTTTATCATCTTCCT-3′; nt381–402) primers for first round. Second round cycling conditions were denaturation at 94 °C for 5 min and then 30 cycles of denaturation at 94 °C for 45 s, annealing at 55 °C for 30 s, elongation at 72 °C for 60 s, and extension at 72 °C for 10 min using HBV381 and HBV801 (5′-CAGCGGCATAAAGGGACTCAAG-3′ nt801–822) primers. Sequencing reactions were set up using big dye sequencing chemistry and two primers: HBV 381 and HBV 801. ZR DNA Sequencing Clean-up Kit (Zymo, Irvine, CA, USA) was used for sequencing clean-up according to the manufacturer’s protocol. Sanger sequencing was performed on an ABI 3130xl genetic analyzer (Applied Biosystems, Foster City, CA, USA).

2.5. Data Analyses

Manual editing of sequences were carried out using Sequencher v5.0 software (Gene Codes Corp., Ann Arbor, MI, USA). Consensus sequences were generated from the overlapping sequences. Next, consensus sequences generated were viewed, trimmed and aligned with all previously generated Botswana reference sequences from GenBank using AliView alignment viewer version 1.28 [23]. Sequences were then uploaded to the Geno2Pheno online database (http://www.geno2Pheno.org, accessed on 4 April 2024) for genotypic, drug resistance and escape mutations analyses. Sequences were further uploaded to a second online database, the Stanford HBVseq database, (http://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html, accessed on 4 April 2024) to confirm genotype and drug resistance mutations. We constructed a maximum-likelihood tree using the best fitting model of nucleotide substitution [TVMe+R2] using IQTREE with 1000 bootstrap replicates [24].

2.6. Statistical Analysis

Predictors associated with HBV positivity were determined using both univariate and multivariable logistic regression, adjusting for clustering by community. Pairwise comparison of median age by community and between HBV negative and positive cases in each community was conducted using Wilcoxon rank-sum test. Kruskal–Wallis test was used to compare the median age across the different communities. To adjust for multi-comparison between communities, the Dunn’s test with Bonferroni correction was used.
Data visualization was performed in R version 4.3.0. Stata version 14.0 (Stata Corp., College Station, TX, USA) was used for statistical analysis and p-values < 0.05 were considered statistically significant.

3. Results

3.1. HBV Prevalence (HBsAg Positivity)

The median age of all participants was 31 (IQR: 24–46) and of these, 63.7% (1360/2135) [95% CI: 61.6–65.7] were female. We report an overall HBV prevalence of 4.0% (86/2135) [95% CI: 3.3–4.9]. Univariate logistic regression analysis shows that participants aged 35 years and older have increased odds of HBV positivity (OR: 1.94; 95% CI: [1.32–2.86]; p = 0.001) (Table 2, Supplementary Figure S1). We observed reduced odds of HBV positivity among people with secondary education (OR: 0.37; 95% CI: [0.17–0.81]; p = 0.012) and those with higher education levels (OR: 0.35; 95% CI: [0.14–0.88 p = 0.025) compared to those with non-formal education. Married participants had increased odds of HBV positivity (OR: 1.67; 95% CI: [1.15–2.41]; p = 0.007) and were older (Table 2, Supplementary Figure S2). There was a trend towards more inconsistent condom use in the HBV positive group compared to the HBV negative group. There were no significant independent predictors of HBV as shown in the multivariate logistic regression in Table 2.
HBsAg HBV prevalence was analysed for the 30 BCPP villages. HBV prevalence r ranged between 0–9.2% with Nata having the highest HBV prevalence among people without HIV, while Mmadinare, Mathangwane, Tsetsejwe and Tati siding reported no HBVsAg positive cases. Figure 1.
Among participants who were older (≥35 years), HBV prevalence in males was 7.8% vs. 4.6% in females, although not statistically significant (p = 0.06), (Supplemental Figure S3, Table 2).

3.2. Age Distribution amongst the Communities

The differences in age by community were determined. There was a significant difference in age by community (Figure 2A,B). There was no significant difference in age between the community with the highest HBV prevalence (Nata), versus those with no HBV positive cases reported (Mmadinare, Mathangwane, Tsetsejwe and Tati siding) (Figure 2B). The differences in HBV status by age in each community was also determined. Four communities without any HBV cases, namely Mmadinare, Mathangwane, Tsetsebjwe and Tati siding, and two communities namely Maunatlala and Nkange with only 1 HBV positive case each, were excluded from the analysis. Overall, HBV positive participants tended to be older as shown in Figure 2C and this difference was statistically significant for Nata (p = 0.001).

3.3. Prevalence by Vaccination Status

There were no HBV vaccination records for the study participants; hence, participants who were ≤21 years were classified as likely to be vaccinated based on the implementation of HBV infant vaccination in Botswana in 2000. The HBV prevalence in the likely vaccinated group was 0.8% (3/363) [95% CI: 0.3–2.4]. The HBV prevalence in the likely unvaccinated group (≥22 years) was 4.7% (83/1772) [95% CI: 3.8–5.8]. There was a statistically significant difference in HBV status between the HBV vaccinated group versus the unvaccinated group, p value = 0.0007.

3.4. HBV Genetic Diversity

Out of the 86 HBV+ samples, n = 13 (15%) were amplified and all of them (100%) were successfully sequenced. The online databases and the phylogenetic analysis revealed that HBV genotype A, n = 7 (54%), was found to be the most predominant circulating HBV genotype while the remaining six sequences were equally shared between genotypes D (23%) and E (23%). The 13 newly generated sequences were used to construct a maximum-likelihood tree and the available online sequences from Botswana were used to confirm genotypes and determine clustering patterns of these sequences with reference sequences. The tree shows that the sequences generated from our study clustered with reference sequences from Botswana (Figure 3).
The 415 bp fragment covered aa 82–210 of the surface region which includes the major hydrophilic region (MHR) (aa 99–169). As depicted in Table 3 below, 38 mutations were found in 12/13 isolates (92.3%) showing amino acid substitution in the HBV surface (s) gene and the overlapping reverse transcriptase (rt) region. Amongst these, 17 were in the s region and 21 in the rt region. Only two mutations were novel. Clinically significant mutations included escape mutations as well as those associated with disease progression and OBI were identified in this study (Table 4). The most common mutations in the s region were sS207N and sA194V found in seven (54%) and six (46%) participants, respectively, (Figure 4A). The most common mutations in the rt region were rtS109P, rtM129L and rtV163I found in seven (54%) each. These three mutations appeared together in six participants (Figure 4B).

4. Discussion

To our knowledge, the current study is the largest study to report HBV prevalence in people without HIV in rural and peri-urban communities in Botswana. The relationship between the prevalence of HBV and participant socioeconomic demographics was explored. We report a 4.0% HBV prevalence which is higher than approximately 1% previously reported in pregnant women without HIV in Botswana and South Africa but similar to a serosurvey in South Africa [3,10,41]. The differences in these prevalence rates might be due to differences in geographic regions, cultural practices, access to healthcare and vaccination coverage as the study on pregnant women was conducted in urban areas while the current study was in peri-urban and rural areas. Differences in HBV prevalence rates even in the same country have been reported before including in Botswana [4,42]. Notably, this prevalence is lower than that reported in PWH in the same communities which was 8% overall [4]. Higher rates of HBV prevalence in PWH compared with people without HIV have been reported before in South Africa [10] while some studies, including a multicentre study which included participants from Botswana, South Africa, Kenya, Malawi, India, Thailand and Brazil, reported similar rates [3,7,43]. The differences might be due to differences in risk factors found in different places as well as the level of immunosuppression in the HIV infected groups. HIV associated immunosuppression has been associated with HBV reactivation resulting in a higher HBsAg positivity [44,45]. In Africa, HBV infections mostly occur during early childhood due to horizontal transmissions while HIV infections are mostly due to sexual transmissions. However, owing to some sexually transmitted cases of HBV in adulthood, and HBV reactivations associated with immunodeficiencies emanating from HIV infection, some studies have found a higher HBV prevalence in PWH. There was a lower HBV prevalence in the likely vaccinated group compared to the unvaccinated group as expected. HBV infant vaccination commenced around 2000 in Botswana including the birth dose [6].
In this study, there were varying HBV prevalence rates across communities, with the highest prevalence recorded in Nata (9.2%) while some places such as Tati, Tsetsebjwe, Mmadinare and Mathangwane reported no HBV cases. Differences in prevalence between communities have been reported before including in PWH in the same communities [4]. Interestingly, the HBV prevalence spread is different between PWH and people without HIV in these communities [4]. For example, Nata had the highest HBV prevalence in people without HIV whereas it had the ninth highest prevalence out of thirty communities in a study on HBV prevalence in PWH. In our current study, Tati and Tsetsebjwe also reported no cases of HBV in people without HIV but had the third and twelfth highest HBV prevalence in the same study of PWH, respectively [4]. There was a difference in age amongst the communities and HBV positive cases were older, particularly in Nata; notably this is the community with the highest HBV prevalence. There was a difference in age amongst the communities. Interestingly, this might not explain the differences in prevalence rates. For example, there was no significant age difference between the community with the highest HBV prevalence and all four communities with no HBV positive cases. Interestingly, HBV positive participants tended to be older, but the difference was statistically only significant for Nata. Although we noticed these differences by age, the HBV rates did not differ by age within the community except in Nata. The differences between the places might be due to cultural practices. It is also possible that the current study randomly selected HBV negative participants as only a subset of samples was screened for HBV.
Older age, marriage and secondary education were predictors of HBV positivity in univariate analysis but there were no predictors of HBV positivity in multivariate analysis. In this study, the older age group are more likely to be unvaccinated as infant vaccination commenced around 2000 when the current study participants were at least adolescents [6]. Married people were also older and hence were likely to be unvaccinated leading to increased odds of HBV positivity. Other studies showed no association with education but showed an association with age [10,44]. The South African study also did not show relationship status as well as the number of lifetime partners as predictors of HBV positivity similar to the current study [10]. Most studies reported more HBV in males; however, for the current study, sex was not a predictor of HBV positivity [4,44,46,47]. More HBV positivity in males has been linked to the effective immune system in females [47]. In a study in PWH in the same communities, the male sex and northern geographic region were independent predictors of HBV positivity unlike in the current study. In the said study with PWH, being older was only a predictor in univariate analysis similar to the current study [4]. Predictors of HBV vary across studies which might be due to lifestyle practices, genotypes as well as host genetics [10,47].
The distribution of the genotypes across peri-urban and rural areas around Botswana will aid in furthering our understanding of the prevalent HBV genotypes amongst people without HIV. Similar to the existing literature on the HBV genotypes circulating in sub-Saharan Africa, the HBV genotypes A (54%), D (23%) and E (23%) were also found to be prevalent in Botswana [8,21]. Genotypes A, D and E from this study clustered together with sequences of known HBV genotypes from Botswana suggesting local transmission. Information on the distribution of HBV genotypes across rural and peri-urban areas in Botswana is limited.
This study identified mutations, some of which were of clinical significance. In the surface region, sA194V and sS207N were the predominant mutations as reported in a study from Kenya [48]. A194V has not been characterized but it has been reported in many studies while sS207N is linked to immune escape [38,39,40]. Other mutations identified which were associated with immune escape were sK122R, sT127P and sS140L which are found in the MHR [28,29,30,31,32,33]. Other mutations with clinical significance were sY100S, sK122R, sM197T, sW201*, sS204R and sS204N which impair the production and secretion of HBsAg, associated with low HBV viral load and OBI [25,26,27,28,29,34,35,37]. In the polymerase region, the most common mutations were rtS109P, rtM129L and rtV163I found in seven participants each similar to other studies which reported these mutations in genotype A and indeed these mutations were present in genotype A in this study [49,50,51]. These three mutations appeared together in six genotype A participants; rtS109P was also found in genotype E. We report no classic drug resistance-associated mutations such as rtL80I/V, rtV173L, rtL180M, rtA181S, rtA194T, rtS202I, rtM204V/I, rtN236T and rtM250L/V associated with resistance against lamivudine, telbivudine, adefovir, entecavir and tenofovir in this study similar to other studies [21,51,52]. The rtY135S mutation was mostly seen in the treatment of non-responders and some studies classified it under drug resistance mutations against lamivudine, telbivudine, adefovir and entecavir but its characterization is not yet concluded [53,54,55,56]. This contrasts with a study in PWH in the same communities which reported a high prevalence of drug resistant mutations against lamivudine [57]. These results might suggest that there were no drug resistant mutations transmitted between PWH and those without HIV. We identified uncharacterized mutations which have been reported in other studies (sE164G, sP188L, sS193L, sA194V, sI195T, sY206N, rtI103V, rtV103I, rtS105T, rtS109P, rtR110G, rtL115V (only found in genotype D), rtN122H, rtF122L, rtN124H, rtQ130P, rtN131D, rtL132M, rtW153R, rtV163I, rtL164M, rtS213T, rtG210R and rtV214E) [21,49,50,54,58,59,60,61,62,63,64,65,66,67,68,69,70]. We also reported novel mutations in this study, sI92C and rtH100M, all found in. genotype E.
This study bears the strength of being the largest study on HBV in people without HIV in understudied rural and peri-urban areas in Botswana. The limitations of the study include insufficient sample volumes which necessitated the use of a dilution protocol which however can be applied in future studies. The effects of insufficient sample volumes were that we could not test for more HBV biomarkers such as HBV surface antibodies and the samples were diluted which might have affected the sequencing success, which was low in our study. The small number of sequences limits genotype distribution and mutations. The community level HBV prevalence should be taken with caution as the study was not powered to determine the prevalence at community level. The small number of samples tested per community limit HBV prevalence comparisons by community. There were no HBV vaccination records and introduction of infant vaccination in Botswana was used to infer vaccination status.

5. Conclusions

We report an HBV prevalence of 4.0% among people without HIV in rural and peri-urban communities in Botswana with varying rates in different communities and the presence of clinically relevant mutations. Furthermore, the HBV prevalence was lower in the likely vaccinated group indicating the success of the vaccination program. Integration of general care, management and advocacy in HBV regardless of HIV status is urgently needed in Botswana to accelerate reductions in the prevalence of HBV among the general population especially in the unvaccinated group. Surveillance of clinically relevant mutations is recommended to guide prevention strategies. Future studies screening for further HBV biomarkers are needed to further characterize HBV in people without HIV in Botswana.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms12061207/s1.

Author Contributions

Conceptualization, M.A. and S.G.; Data curation, T.M., B.B.P., G.M., W.T.C., B.P., L.N.B., D.D., K.B., L.M.-D., L.O. and T.R.; Formal analysis, M.A., T.M., B.B.P., L.N.B., G.M., W.T.C., B.P., T.R., S.M. and S.G.; Funding acquisition, M.A.; Methodology, M.A., B.B.P., G.M., W.T.C., B.P., L.N.B., K.B., S.M. and S.G. Resources, C.O.A., T.G., J.M., R.S., S.L., S.M. and S.G.; Supervision, M.A., C.O.A., T.G., J.M., R.S., S.L., and S.G.; Validation, M.A., B.B.P., G.M., W.T.C., S.M. and S.G., Writing—original draft, M.A. and T.M.; Writing—review &; editing, M.A., T.M., B.B.P., G.M., C.O.A., W.T.C., B.P., L.N.B., D.D., K.B., L.M.-D., L.O., T.R., T.G., J.M., R.S., S.L., S.M. and S.G. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Wellcome Trust (grant number 218770/Z/19/Z) and Bill & Melinda Gates Foundation (INV-033558). B.B.P. and S.G. are supported by the National Institutes of Health (NIH) Common Fund, award number U41HG006941 (H3ABioNet). H3ABioNet is an initiative of the Human Health and Heredity in Africa Consortium (H3Africa) program of the African Academy of Science. B.B.P., R.M., and S.M. are also supported by Trials of Excellence in Southern Africa (TESAIII), which is part of the EDCTP2 program supported by the European Union (grant number CSA2020NoE-3104 TESAIII). S.L., R.S. and S.M. received support from the NIH (award numbers K24 AI131928, K24 AI131924 and K43 TW012350, respectively). W.T.C., S.M., and S.G. are partly supported through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE 2.0) from the Bill & Melinda Gates Foundation (INV-033558). S.G., MA and B.B.P are supported by the Fogarty International Center at the US National Institutes of Health (D43 TW009610). S.G, MA and W.T.C are supported partly by NIH (award number 1G11TW012503-01). The views and opinions in this manuscript are solely those of the authors and do not represent the official position of the funding agencies. The funders had no role in the design, conduct of the study and decision to publish the results.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors on request.

Acknowledgments

The authors thank the Botswana Prevention Combination Project study participants, Dikgosi and other community leaders, the clinic staff, District Health Management Teams, and Community Health Facilities at study sites; the ‘Ya Tsie’ Study Team at the Botswana Harvard Health Partnership, the Harvard T. H. Chan School of Public Health, the Centers for Disease Control and Prevention (CDC) Botswana, CDC Atlanta, and the Botswana Ministry of Health. The authors also thank those who served on the Ya Tsie Community Advisory Board, Laboratory Staff, and Management of Botswana Harvard HIV Reference Laboratory.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. WHO. Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries; World Health Organization: Geneva, Switzerland, 2024. [Google Scholar]
  2. Anderson, M.; Gaseitsiwe, S.; Moyo, S.; Thami, K.P.; Mohammed, T.; Setlhare, D.; Sebunya, T.K.; Powell, E.A.; Makhema, J.; Blackard, J.T.; et al. Slow CD4(+) T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana. Open Forum Infect. Dis. 2016, 3, ofw140. [Google Scholar] [CrossRef] [PubMed]
  3. Mbangiwa, T.; Kasvosve, I.; Anderson, M.; Thami, P.K.; Choga, W.T.; Needleman, A.; Phinius, B.B.; Moyo, S.; Leteane, M.; Leidner, J.; et al. Chronic and Occult Hepatitis B Virus Infection in Pregnant Women in Botswana. Genes 2018, 9, 259. [Google Scholar] [CrossRef] [PubMed]
  4. Phinius, B.B.; Anderson, M.; Gobe, I.; Mokomane, M.; Choga, W.T.; Mutenga, S.R.; Mpebe, G.; Pretorius-Holme, M.; Musonda, R.; Gaolathe, T.; et al. High Prevalence of Hepatitis B Virus Infection Among People With HIV in Rural and Periurban Communities in Botswana. Open Forum Infect. Dis. 2023, 10, ofac707. [Google Scholar] [CrossRef] [PubMed]
  5. Wester, C.W.; Bussmann, H.; Moyo, S.; Avalos, A.; Gaolathe, T.; Ndwapi, N.; Essex, M.; MacGregor, R.R.; Marlink, R.G. Serological evidence of HIV-associated infection among HIV-1-infected adults in Botswana. Clin. Infect. Dis. 2006, 43, 1612–1615. [Google Scholar] [CrossRef] [PubMed]
  6. Patel, P.; Davis, S.; Tolle, M.; Mabikwa, V.; Anabwani, G. Prevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana. Am. J. Trop. Med. Hyg. 2011, 85, 390–394. [Google Scholar] [CrossRef] [PubMed]
  7. Greer, A.E.; Ou, S.S.; Wilson, E.; Piwowar-Manning, E.; Forman, M.S.; McCauley, M.; Gamble, T.; Ruangyuttikarn, C.; Hosseinipour, M.C.; Kumarasamy, N.; et al. Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J. Acquir. Immune Defic. Syndr. 2017, 76, 388–393. [Google Scholar] [CrossRef] [PubMed]
  8. Choga, W.T.; Anderson, M.; Zumbika, E.; Moyo, S.; Mbangiwa, T.; Phinius, B.B.; Melamu, P.; Kayembe, M.K.; Kasvosve, I.; Sebunya, T.K.; et al. Molecular characterization of hepatitis B virus in blood donors in Botswana. Virus Genes 2019, 55, 33–42. [Google Scholar] [CrossRef]
  9. Adewumi, M.O.; Donbraye, E.; Sule, W.F.; Olarinde, O. HBV Infection Among HIV-Infected Cohort and HIV-Negative Hospital Attendees in South Western Nigeria. Afr. J. Infect. Dis. 2015, 9, 14–17. [Google Scholar] [CrossRef] [PubMed]
  10. Samsunder, N.; Ngcapu, S.; Lewis, L.; Baxter, C.; Cawood, C.; Khanyile, D.; Kharsany, A.B.M. Seroprevalence of hepatitis B virus: Findings from a population-based household survey in KwaZulu-Natal, South Africa. Int. J. Infect. Dis. 2019, 85, 150–157. [Google Scholar] [CrossRef]
  11. Kramvis, A. Genotypes and genetic variability of hepatitis B virus. Intervirology 2014, 57, 141–150. [Google Scholar] [CrossRef]
  12. Kramvis, A.; Kew, M.; Francois, G. Hepatitis B virus genotypes. Vaccine 2005, 23, 2409–2423. [Google Scholar] [CrossRef] [PubMed]
  13. Norder, H.; Courouce, A.M.; Coursaget, P.; Echevarria, J.M.; Lee, S.D.; Mushahwar, I.K.; Robertson, B.H.; Locarnini, S.; Magnius, L.O. Genetic diversity of hepatitis B virus strains derived worldwide: Genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004, 47, 289–309. [Google Scholar] [CrossRef] [PubMed]
  14. Kramvis, A. Molecular characteristics and clinical relevance of African genotypes and subgenotypes of hepatitis B virus. S. Afr. Med. J. 2018, 108, 17–21. [Google Scholar] [PubMed]
  15. Kramvis, A. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev. Med. Virol. 2016, 26, 285–303. [Google Scholar] [CrossRef] [PubMed]
  16. Anderson, M.; Gaseitsiwe, S.; Moyo, S.; Wessels, M.J.; Mohammed, T.; Sebunya, T.K.; Powell, E.A.; Makhema, J.; Blackard, J.T.; Marlink, R.; et al. Molecular characterisation of hepatitis B virus in HIV-1 subtype C infected patients in Botswana. BMC Infect. Dis. 2015, 15, 335. [Google Scholar] [CrossRef] [PubMed]
  17. Sonderup, M.W.; Spearman, C.W. Global Disparities in Hepatitis B Elimination-A Focus on Africa. Viruses 2022, 14, 82. [Google Scholar] [CrossRef] [PubMed]
  18. WHO. Global Health Sector Strategy on Viral Hepatitis 2016–2021. Towards Ending Viral Hepatitis 2016. Available online: https://iris.who.int/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1 (accessed on 15 April 2024).
  19. Makhema, J.; Wirth, K.E.; Pretorius Holme, M.; Gaolathe, T.; Mmalane, M.; Kadima, E.; Chakalisa, U.; Bennett, K.; Leidner, J.; Manyake, K.; et al. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. N. Engl. J. Med. 2019, 381, 230–242. [Google Scholar] [CrossRef] [PubMed]
  20. Gaolathe, T.; Wirth, K.E.; Holme, M.P.; Makhema, J.; Moyo, S.; Chakalisa, U.; Yankinda, E.K.; Lei, Q.; Mmalane, M.; Novitsky, V.; et al. Botswana’s progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: A population-based survey. Lancet HIV 2016, 3, e221–e230. [Google Scholar] [CrossRef] [PubMed]
  21. Anderson, M.; Choga, W.T.; Moyo, S.; Bell, T.G.; Mbangiwa, T.; Phinius, B.B.; Bhebhe, L.; Sebunya, T.K.; Lockman, S.; Marlink, R.; et al. Molecular Characterization of Near Full-Length Genomes of Hepatitis B Virus Isolated from Predominantly HIV Infected Individuals in Botswana. Genes 2018, 9, 453. [Google Scholar] [CrossRef]
  22. Ma, Y.; Ding, Y.; Juan, F.; Dou, X.G. Genotyping the hepatitis B virus with a fragment of the HBV DNA polymerase gene in Shenyang, China. Virol. J. 2011, 8, 315. [Google Scholar] [CrossRef]
  23. Larsson, A. AliView: A fast and lightweight alignment viewer and editor for large datasets. Bioinformatics 2014, 30, 3276–3278. [Google Scholar] [CrossRef] [PubMed]
  24. Nguyen, L.T.; Schmidt, H.A.; von Haeseler, A.; Minh, B.Q. IQ-TREE: A fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 2015, 32, 268–274. [Google Scholar] [CrossRef] [PubMed]
  25. Svicher, V.; Cento, V.; Bernassola, M.; Neumann-Fraune, M.; Van Hemert, F.; Chen, M.; Salpini, R.; Liu, C.; Longo, R.; Visca, M.; et al. Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antivir. Res. 2012, 93, 86–93. [Google Scholar] [CrossRef] [PubMed]
  26. Mello, F.C.; Martel, N.; Gomes, S.A.; Araujo, N.M. Expression of Hepatitis B Virus Surface Antigen Containing Y100C Variant Frequently Detected in Occult HBV Infection. Hepat. Res. Treat. 2011, 2011, 695859. [Google Scholar] [CrossRef]
  27. Biswas, S.; Candotti, D.; Allain, J.P. Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection. J. Virol. 2013, 87, 7882–7892. [Google Scholar] [CrossRef] [PubMed]
  28. Wang, J.; Liu, Y.; Liao, H.; Liu, L.; Chen, R.; Si, L.; Luo, D.; Huang, B.; Li, L.; Jiang, J.; et al. The sK122R mutation of hepatitis B virus (HBV) is associated with occult HBV infection: Analysis of a large cohort of Chinese patients. J. Clin. Virol. 2020, 130, 104564. [Google Scholar] [CrossRef] [PubMed]
  29. Wang, H.; Wang, M.; Huang, J.; Xu, R.; Liao, Q.; Shan, Z.; Zheng, Y.; Rong, X.; Tang, X.; Li, T.; et al. Novel hepatitis B virus surface antigen mutations associated with occult genotype B hepatitis B virus infection affect HBsAg detection. J. Viral. Hepat. 2020, 27, 915–921. [Google Scholar] [CrossRef] [PubMed]
  30. Martin, C.M.; Welge, J.A.; Rouster, S.D.; Shata, M.T.; Sherman, K.E.; Blackard, J.T. Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro. J. Viral. Hepat. 2012, 19, 716–723. [Google Scholar] [CrossRef]
  31. Luongo, M.; Critelli, R.; Grottola, A.; Gitto, S.; Bernabucci, V.; Bevini, M.; Vecchi, C.; Montagnani, G.; Villa, E. Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: Sequence analysis and therapeutic strategy. J. Clin. Virol. 2015, 62, 89–91. [Google Scholar] [CrossRef]
  32. Ijaz, S.; Ferns, R.B.; Tedder, R.S. A ‘first loop’ linear epitope accessible on native hepatitis B surface antigen that persists in the face of ‘second loop’ immune escape. J. Gen. Virol. 2003, 84 Pt 2, 269–275. [Google Scholar] [CrossRef]
  33. Osasona, O.G.; Oguntoye, O.O.; Arowosaye, A.O.; Abdulkareem, L.O.; Adewumi, M.O.; Happi, C.; Folarin, O. Patterns of hepatitis b virus immune escape and pol/rt mutations across clinical cohorts of patients with genotypes a, e and occult hepatitis b infection in Nigeria: A multi-centre study. Virulence 2023, 14, 2218076. [Google Scholar] [CrossRef] [PubMed]
  34. Mirabelli, C.; Surdo, M.; Van Hemert, F.; Lian, Z.; Salpini, R.; Cento, V.; Cortese, M.F.; Aragri, M.; Pollicita, M.; Alteri, C.; et al. Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. J. Infect. 2015, 70, 288–298. [Google Scholar] [CrossRef] [PubMed]
  35. Zhou, H.; Gewaily, D.; Ahn, S.H.; Preskill, C.; Wang, Y.; Zong, L.; Zhang, J.; Han, K.H.; Wands, J.; Li, J.; et al. Sequence analysis and functional characterization of full-length hepatitis B virus genomes from Korean cirrhotic patients with or without liver cancer. Virus Res. 2017, 235, 86–95. [Google Scholar] [CrossRef] [PubMed]
  36. Thi Cam Huong, N.; Trung, N.Q.; Luong, B.A.; Tram, D.B.; Vu, H.A.; Bui, H.H.; Pham Thi Le, H. Mutations in the HBV PreS/S gene related to hepatocellular carcinoma in Vietnamese chronic HBV-infected patients. PLoS ONE 2022, 17, e0266134. [Google Scholar] [CrossRef] [PubMed]
  37. Kalinina, T.; Riu, A.; Fischer, L.; Will, H.; Sterneck, M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology 2001, 34, 385–394. [Google Scholar] [CrossRef] [PubMed]
  38. Weinberger, K.M.; Bauer, T.; Bohm, S.; Jilg, W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J. Gen. Virol. 2000, 81 Pt 5, 1165–1174. [Google Scholar] [CrossRef]
  39. Zheng, X.; Weinberger, K.M.; Gehrke, R.; Isogawa, M.; Hilken, G.; Kemper, T.; Xu, Y.; Yang, D.; Jilg, W.; Roggendorf, M.; et al. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. Virology 2004, 329, 454–464. [Google Scholar] [CrossRef]
  40. Coppola, N.; Onorato, L.; Minichini, C.; Di Caprio, G.; Starace, M.; Sagnelli, C.; Sagnelli, E. Clinical significance of hepatitis B surface antigen mutants. World J. Hepatol. 2015, 7, 2729–2739. [Google Scholar] [CrossRef] [PubMed]
  41. Joseph Davey, D.; Hsiao, N.Y.; Wendy Spearman, C.; Sonderup, M.; Hu, N.C.; Mashele, N.; Mvududu, R.; Myer, L. Low prevalence of hepatitis B virus infection in HIV-uninfected pregnant women in Cape Town, South Africa: Implications for oral pre-exposure prophylaxis roll out. BMC Infect. Dis. 2022, 22, 719. [Google Scholar] [CrossRef]
  42. Matthews, P.C.; Carlson, J.M.; Beloukas, A.; Malik, A.; Jooste, P.; Ogwu, A.; Shapiro, R.; Riddell, L.; Chen, F.; Luzzi, G.; et al. HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. J. Infect. Dis. 2016, 213, 1248–1252. [Google Scholar] [CrossRef]
  43. Amponsah-Dacosta, E.; Lebelo, R.L.; Rakgole, J.N.; Burnett, R.J.; Selabe, S.G.; Mphahlele, M.J. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa. J. Med. Virol. 2014, 86, 918–924. [Google Scholar] [CrossRef] [PubMed]
  44. Msomi, N.; Naidoo, K.; Yende-Zuma, N.; Padayatchi, N.; Govender, K.; Singh, J.A.; Abdool-Karim, S.; Abdool-Karim, Q.; Mlisana, K. High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa. BMC Infect. Dis. 2020, 20, 847. [Google Scholar] [CrossRef] [PubMed]
  45. Phinius, B.B.; Anderson, M.; Bokete, R.; Mbangiwa, T.; Choga, W.T.; Baruti, K.; Makhema, J.; Musonda, R.; Blackard, J.T.; Essex, M.; et al. Incidence of hepatitis B virus infection among human immunodeficiency virus-infected treatment naive adults in Botswana. Medicine 2020, 99, e19341. [Google Scholar] [CrossRef] [PubMed]
  46. Yuen, M.F.; Yuan, H.J.; Wong, D.K.; Yuen, J.C.; Wong, W.M.; Chan, A.O.; Wong, B.C.; Lai, K.C.; Lai, C.L. Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 2005, 54, 1610–1614. [Google Scholar] [CrossRef] [PubMed]
  47. Brown, R.; Goulder, P.; Matthews, P.C. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res. 2022, 7, 32. [Google Scholar] [CrossRef] [PubMed]
  48. King, R.E.; Kimotho, J.; Macharia, R.; Ndung’u, F.N.; Nzou, S.M.; Irekwa, R.M. Identification and Characterization of Hepatitis B Virus Immune Escape Mutants in Kenya. Am. J. Mol. Biol. 2023, 13, 1–17. [Google Scholar] [CrossRef]
  49. Mathew, A.; Ismael, N.; Meeds, H.; Vubil, A.; Zicai, A.F.; Mabunda, N.; Blackard, J.T. Hepatitis B virus genotypes and drug resistance mutations circulating in blood donors in Beira, Mozambique. PLoS ONE 2023, 18, e0281855. [Google Scholar] [CrossRef] [PubMed]
  50. Ismail, A.M.; Samuel, P.; Eapen, C.E.; Kannangai, R.; Abraham, P. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naive hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology 2012, 55, 36–44. [Google Scholar] [CrossRef] [PubMed]
  51. Koyaweda, G.W.; Ongus, J.R.; Machuka, E.; Juma, J.; Macharia, R.; Komas, N.P.; Pelle, R. Detection of circulating hepatitis B virus immune escape and polymerase mutants among HBV-positive patients attending Institut Pasteur de Bangui, Central African Republic. Int. J. Infect. Dis. 2020, 90, 138–144. [Google Scholar] [CrossRef]
  52. Pacheco, S.R.; Dos Santos, M.; Stocker, A.; Zarife, M.A.S.; Schinoni, M.I.; Parana, R.; Dos Reis, M.G.; Silva, L.K. Genotyping of HBV and tracking of resistance mutations in treatment-naive patients with chronic hepatitis B. Infect. Drug Resist. 2017, 10, 201–207. [Google Scholar] [CrossRef]
  53. Mahmood, M.; Jameel, S.; Rahman, Z.U.; Anwar, M.A. Molecular Analysis of Hepatitis B Virus Reverse Transcriptase Domain for Mutations Associated with Viral Resistance in Pakistani Patients. Viral Hepat. J. 2021, 27, 153–158. [Google Scholar] [CrossRef]
  54. Singla, B.; Bhattacharyya, R.; Chakraborti, A.; Sharma, B.K.; Kapil, S.; Chawla, Y.K.; Arora, S.K.; Das, A.; Dhiman, R.K.; Duseja, A. Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. Gene 2015, 567, 22–30. [Google Scholar] [CrossRef] [PubMed]
  55. Gohar, M.; Rehman, I.U.; Ullah, A.; Khan, M.A.; Yasmin, H.; Ahmad, J.; Butt, S.; Ahmad, A. Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients. Microorganisms 2023, 11, 2622. [Google Scholar] [CrossRef] [PubMed]
  56. Tan, J.; Degertekin, B.; Wong, S.N.; Husain, M.; Oberhelman, K.; Lok, A.S. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 2008, 48, 391–398. [Google Scholar] [CrossRef] [PubMed]
  57. Phinius, B.B.; Anderson, M.; Gobe, I.; Mokomane, M.; Choga, W.T.; Phakedi, B.; Ratsoma, T.; Mpebe, G.; Makhema, J.; Shapiro, R.; et al. High Prevalence of Hepatitis B Virus Drug Resistance Mutations to Lamivudine among People with HIV/HBV Coinfection in Rural and Peri-Urban Communities in Botswana. Viruses 2024, 16, 592. [Google Scholar] [CrossRef] [PubMed]
  58. Bubonja-Sonje, M.; Peruc, D.; Abram, M.; Mohar-Vitezic, B. Prevalence of occult hepatitis B virus infection and characterisation of hepatitis B surface antigen mutants among adults in western Croatia. Ann. Hepatol. 2024, 29, 101156. [Google Scholar] [CrossRef] [PubMed]
  59. Oluyinka, O.O.; Tong, H.V.; Bui Tien, S.; Fagbami, A.H.; Adekanle, O.; Ojurongbe, O.; Bock, C.T.; Kremsner, P.G.; Velavan, T.P. Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks. PLoS ONE 2015, 10, e0131912. [Google Scholar] [CrossRef] [PubMed]
  60. Wang, L.; Liu, H.; Ning, X.; Gao, F. Sequence analysis of the S gene region in HBV DNA from patients positive for both HBsAg and HBsAb tests. Hepatol. Res. 2010, 40, 1212–1218. [Google Scholar] [CrossRef] [PubMed]
  61. Logoida, M.; Kristian, P.; Schreiberova, A.; Lenartova, P.D.; Bednarova, V.; Hatalova, E.; Hockickova, I.; Drazilova, S.; Jarcuska, P.; Janicko, M.; et al. Comparison of Two Diagnostic Methods for the Detection of Hepatitis B Virus Genotypes in the Slovak Republic. Pathogens 2021, 11, 20. [Google Scholar] [CrossRef]
  62. Hosseini, S.Y.; Sanaei, N.; Fattahi, M.R.; Malek-Hosseini, S.A.; Sarvari, J. Association of HBsAg mutation patterns with hepatitis B infection outcome: Asymptomatic carriers versus HCC/cirrhotic patients. Ann. Hepatol. 2019, 18, 640–645. [Google Scholar] [CrossRef] [PubMed]
  63. Kuhns, M.C.; Holzmayer, V.; Anderson, M.; McNamara, A.L.; Sauleda, S.; Mbanya, D.; Duong, P.T.; Dung, N.T.T.; Cloherty, G.A. Molecular and Serological Characterization of Hepatitis B Virus (HBV)-Positive Samples with Very Low or Undetectable Levels of HBV Surface Antigen. Viruses 2021, 13, 2053. [Google Scholar] [CrossRef] [PubMed]
  64. Malve, B.; Eschlimann, M.; Galgey, S.; Fenaux, H.; Zoulim, F.; Goehringer, F.; Rabaud, C.; May, T.; Jeulin, H.; Schvoerer, E. Impact of deletions and mutations in Hepatitis B virus envelope proteins on serological profile and clinical evolution. Virus Res. 2017, 238, 141–147. [Google Scholar] [CrossRef] [PubMed]
  65. Ijaz, S.; Szypulska, R.; Andrews, N.; Tedder, R.S. Investigating the impact of hepatitis B virus surface gene polymorphism on antigenicity using ex vivo phenotyping. J. Gen. Virol. 2012, 93 Pt 11, 2473–2479. [Google Scholar] [CrossRef] [PubMed]
  66. Enriquez-Navarro, K.; Maldonado-Rodriguez, A.; Rojas-Montes, O.; Torres-Ibarra, R.; Bucio-Ortiz, L.; De la Cruz, M.A.; Torres-Flores, J.; Xoconostle-Cazares, B.; Lira, R. Identification of mutations in the S gene of hepatitis B virus in HIV positive Mexican patients with occult hepatitis B virus infection. Ann. Hepatol. 2020, 19, 507–515. [Google Scholar] [CrossRef] [PubMed]
  67. Choga, W.T.; Anderson, M.; Zumbika, E.; Phinius, B.B.; Mbangiwa, T.; Bhebhe, L.N.; Baruti, K.; Kimathi, P.O.; Seatla, K.K.; Musonda, R.M.; et al. In Silico Prediction of Human Leukocytes Antigen (HLA) Class II Binding Hepatitis B Virus (HBV) Peptides in Botswana. Viruses 2020, 12, 731. [Google Scholar] [CrossRef] [PubMed]
  68. Panigrahi, R.; Biswas, A.; De, B.K.; Chakrabarti, S.; Chakravarty, R. Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected population. Virol. J. 2013, 10, 56. [Google Scholar] [CrossRef] [PubMed]
  69. Makondo, E.; Bell, T.G.; Kramvis, A. Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa. PLoS ONE 2012, 7, e46345. [Google Scholar] [CrossRef]
  70. Quiros-Roldan, E.; Calabresi, A.; Lapadula, G.; Tirelli, V.; Costarelli, S.; Cologni, G.; Zaltron, S.; Puoti, M.; Carosi, G.; Torti, C. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. Antivir. Ther. 2008, 13, 341–348. [Google Scholar] [CrossRef]
Microorganisms 12 01207 g001
Figure 1. HBV prevalence by community among people without HIV from the BCPP cohort.
Figure 1. HBV prevalence by community among people without HIV from the BCPP cohort.
Microorganisms 12 01207 g001
Microorganisms 12 01207 g002aMicroorganisms 12 01207 g002b
Figure 2. (A) Age by community, (B) Heat map showing differences in age distribution between communities, (C) Boxplots showing the age distribution across the BCPP communities with both HBV negative (green) and positive (orange) cases. Pairwise comparison was conducted by age between communities and between HBV negative and positive cases using Wilcoxon test. The significance levels of ns, *, **, and *** represent p-values > 0.05, <0.05, <0.01 and <0.001, respectively.
Figure 2. (A) Age by community, (B) Heat map showing differences in age distribution between communities, (C) Boxplots showing the age distribution across the BCPP communities with both HBV negative (green) and positive (orange) cases. Pairwise comparison was conducted by age between communities and between HBV negative and positive cases using Wilcoxon test. The significance levels of ns, *, **, and *** represent p-values > 0.05, <0.05, <0.01 and <0.001, respectively.
Microorganisms 12 01207 g002aMicroorganisms 12 01207 g002b
Microorganisms 12 01207 g003
Figure 3. Phylogenetic analysis of HBV strains obtained from HIV-uninfected participants living in rural and peri-urban areas in Botswana. A phylogenetic analysis of a 415 bp fragment of the HBV from different isolates with seven HBV A, three HBV D and three HBV E sequences clustered with the matching HBV genotype Botswana reference. Study sequences are denoted by the name HBV followed by a number and the references begin with an accession number followed by a letter denoting the genotype. Genotype A is coloured red, D is coloured blue and E is coloured green. Black is genotype G which was used for rooting.
Figure 3. Phylogenetic analysis of HBV strains obtained from HIV-uninfected participants living in rural and peri-urban areas in Botswana. A phylogenetic analysis of a 415 bp fragment of the HBV from different isolates with seven HBV A, three HBV D and three HBV E sequences clustered with the matching HBV genotype Botswana reference. Study sequences are denoted by the name HBV followed by a number and the references begin with an accession number followed by a letter denoting the genotype. Genotype A is coloured red, D is coloured blue and E is coloured green. Black is genotype G which was used for rooting.
Microorganisms 12 01207 g003
Microorganisms 12 01207 g004aMicroorganisms 12 01207 g004b
Figure 4. (A) Frequency of surface region mutations, (B) Frequency of rt region mutations. *: stop codon.
Figure 4. (A) Frequency of surface region mutations, (B) Frequency of rt region mutations. *: stop codon.
Microorganisms 12 01207 g004aMicroorganisms 12 01207 g004b
Table 1. The distribution of participants per community.
Table 1. The distribution of participants per community.
VillageTotal Number of ParticipantsTested (n = 2135)
Metsimotlhabe394104
Molapowabojang3440
Oodi377101
Digawana18977
Bokaa36681
Otse3770
Letlhakeng41194
Gumare399103
Rakops36290
Mmankgodi34986
Lentsweletau308105
Gweta35689
Shoshong32968
Tati Siding34187
Shakawe379104
Ranaka13568
Sebina19042
Mmadunyane22256
Masunga33580
Nata33787
Sefhare27574
Mmathethe27774
Ramokgonami24467
Mmadinare30182
Mathwangwane25442
Sefophe29663
Lerala31773
Nkange11435
Tsetsebjwe22962
Maunatlala16741
Table 2. Univariate and multivariate analysis of demographic factors associated with HBV positivity.
Table 2. Univariate and multivariate analysis of demographic factors associated with HBV positivity.
CharacteristicHBV+ (n = 86)HBV− (n = 2049)Univariate Logistic RegressionMultivariate Logistic Regression
OR (95% CI)p-ValueaOR (95% CI)p-Value
Sex, n (%)
Female49 (57.0)1311 (64.0)Ref Ref
Male37 (43.0)739 (36.0)1.34 (0.73–2.46)0.341.41 (0.77–2.58)0.27
Age category, n (%)
<3538 (44.2)1242 (60.6)Ref Ref
≥3548 (55.8)807 (39.4)1.94 (1.32–2.86)0.0011.40 (1.76–2.58)0.28
Marital status, n (%)
Single or never married58 (67.4)1557 (76.0)Ref Ref
Married26 (30.2)419 (20.5)1.67 (1.15–2.41)0.0071.15 (0.68–1.92)0.61
Widowed/Divorced/separated2 (2.3)73 (3.5)0.74 (0.9–2.87)0.660.43 (0.10–1.82)0.25
Region, n (%)
South30 (34.9)760 (37.1)Ref
Central23 (26.7)639 (31.2)0.91 (0.51–1.62)0.75
North33 (38.4)650 (31.7)1.29 (0.74–2.24)0.38
Number of lifetime sexual partners (n = 1952)
<1068 (82.9)1608 (86.0)Ref
≥1014 (17.1)262 (14.0)1.26 (0.64–2.48)0.50
Education level, n (%)
Non-formal19 (22.1)216 (10.6)Ref Ref
Primary19 (22.1)335 (16.4)0.64 (0.29–1.42)0.280.64 (0.28–1.46)0.29
Secondary37 (43.0)1133 (55.5)0.37 (0.17–0.81)0.0120.45 (0.16–1.22)0.12
Higher than senior secondary11 (12.8)359 (17.5)0.35 (0.14–0.88)0.0250.41 (0.14–1.17)0.10
Employment
Unemployed54 (62.8)1444 (70.5)Ref
Employed32 (37.2)605 (29.5)1.41(0.88–2.31)0.17
Circumcised (n = 775)
No29 (78.4)495 (67.1)Ref
Yes8 (21.6)241 (32.7)0.57 (0.29–1.12)0.10
Inconsistent condom use (n = 1632)
Yes48 (73.9)943 (60.2)Ref
No17 (26.2)624 (39.8)0.54 (0.28–1.04)0.06
Age at First Sex
<1822 (31.9)487 (29.7)Ref
≥1847 (68.1)1155 (70.34)0.90 (0.58–1.40)0.64
Abbreviations: HBV; hepatitis B virus, OR; Odds ratio, aOR; adjusted Odds ratio, HBV+; hepatitis B virus positive, HBV−; hepatitis B virus negative.
Table 3. HBV mutations.
Table 3. HBV mutations.
Sample IDGenotypeSubstitution rtSubstitution S
MA1E
MA2ArtS109P, rtM129L, rtW153R, rtV163IsS193L, sS207N
MA3ArtS109P, rtN122H, rtM129L, rtV163IsA194V, sS207N
MA4DrtL115V, rtF122L, rtQ130P, rtY135S, rtG210RsT127P, sW201 *
MA5ArtI103V, rtS109P, rtN122H, rtM129L, rtW153R, rtV163IsA194V, sS207N
MA6ArtS109P, rtN122H, rtM129L, rtV163IsA194V, sS207N
MA7ArtI103V, rtS109P, rtN122H, rtM129L, rtW153R, rtV163IsA194V, sP203R, sS207N
MA8DrtV103I, rtL115V, rtF122L, rtQ130P, rtY135S, rtS213TsT127P, sS204R
MA9ArtS105T, rtR110G, rtM129L, rtV163IsS193L, sA194V, sI195T, sM197T, sS204N, Ss207N
MA10ErtH100M, rtS109PsI92C, sS140L
MA11ErtL132MsP188L
MA12ArtS109P, rtN122H, rtN124H, rtM129L, rtN131D, rtV163IsK122R, sA194V, sS207N
MA13DrtL115V, rtF122L, rtQ130P, rtY135S, rtL164M, rtV214EsY100S, sT127P, sE164G, sY206N
Abbreviation: rt: reverse transcriptase, s: surface. Bold = novel, *: stop codon.
Table 4. Clinical significance of identified HBV mutations.
Table 4. Clinical significance of identified HBV mutations.
MutationGenotypeClinical Significance
rtH100MENot characterized
rtI103VANot characterized
rtV103IDNot characterized
rtS105TANot characterized
rtS109PA, ENot characterized
rtR110GANot characterized
rtL115VDNot characterized
rtN122HANot characterized
rtF122LDNot characterized
rtN124HANot characterized
rtM129LANot characterized
rtQ130PDNot characterized
rtN131DANot characterized
rtL132MENot characterized
rtY135SDPartly linked to drug resistance
rtW153RANot characterized
rtV163IANot characterized
rtL164MDNot characterized
rtS213TDNot characterized
rtG210RDNot characterized
rtV214EDNot characterized
sI92CENot characterized
sY100SDImpair production and secretion of HBsAg, associated with OBI [25,26,27]
sK122RAImmune escape, Associated with OBI [28,29,30]
sT127PDImmune escape [31,32]
sS140LEImmune escape [33]
sE164GDNot characterized
sP188LENot characterized
sS193LANot characterized
sA194VANot characterized
sI195TANot characterized
sM197TACorrelate with low HBV viral load [34]
sW201 *DReduces intracellular HBsAg [35]
sP203RAAssociated with HCC [36]
sS204RDReduces HBsAg secretion [37]
sS204NACorrelate with low HBV viral load [34]
sY206NDNot characterized
sS207NAImmune escape [38,39,40]
Abbreviation: rt: reverse transcriptase, s: surface. Bold = novel, *: stop codon.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Anderson, M.; Mangogola, T.; Phinius, B.B.; Mpebe, G.; Aimakhu, C.O.; Choga, W.T.; Phakedi, B.; Bhebhe, L.N.; Ditshwanelo, D.; Baruti, K.; et al. Hepatitis B Virus Prevalence among HIV-Uninfected People Living in Rural and Peri-Urban Areas in Botswana. Microorganisms 2024, 12, 1207. https://doi.org/10.3390/microorganisms12061207

AMA Style

Anderson M, Mangogola T, Phinius BB, Mpebe G, Aimakhu CO, Choga WT, Phakedi B, Bhebhe LN, Ditshwanelo D, Baruti K, et al. Hepatitis B Virus Prevalence among HIV-Uninfected People Living in Rural and Peri-Urban Areas in Botswana. Microorganisms. 2024; 12(6):1207. https://doi.org/10.3390/microorganisms12061207

Chicago/Turabian Style

Anderson, Motswedi, Thabo Mangogola, Bonolo B. Phinius, Gorata Mpebe, Christopher O. Aimakhu, Wonderful T. Choga, Basetsana Phakedi, Lynnette N. Bhebhe, Doreen Ditshwanelo, Kabo Baruti, and et al. 2024. "Hepatitis B Virus Prevalence among HIV-Uninfected People Living in Rural and Peri-Urban Areas in Botswana" Microorganisms 12, no. 6: 1207. https://doi.org/10.3390/microorganisms12061207

APA Style

Anderson, M., Mangogola, T., Phinius, B. B., Mpebe, G., Aimakhu, C. O., Choga, W. T., Phakedi, B., Bhebhe, L. N., Ditshwanelo, D., Baruti, K., Mpofu-Dobo, L., Othusitse, L., Ratsoma, T., Gaolathe, T., Makhema, J., Shapiro, R., Lockman, S., Moyo, S., & Gaseitsiwe, S. (2024). Hepatitis B Virus Prevalence among HIV-Uninfected People Living in Rural and Peri-Urban Areas in Botswana. Microorganisms, 12(6), 1207. https://doi.org/10.3390/microorganisms12061207

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop